

SECOND REGULAR SESSION

SENATE BILL NO. 953

99TH GENERAL ASSEMBLY

INTRODUCED BY SENATOR SATER.

Read 1st time January 23, 2018, and ordered printed.

ADRIANE D. CROUSE, Secretary.

6099S.01I

AN ACT

To repeal sections 195.015 and 195.017, RSMo, and to enact in lieu thereof two new sections relating to schedules of controlled substances.

Be it enacted by the General Assembly of the State of Missouri, as follows:

Section A. Sections 195.015 and 195.017, RSMo, are repealed and two new
2 sections enacted in lieu thereof, to be known as sections 195.015 and 195.017, to
3 read as follows:

195.015. 1. The department of health and senior services shall administer
2 this chapter and may add substances to the schedules after public notice and
3 hearing. In making a determination regarding a substance, the department of
4 health and senior services shall consider the following:

- 5 (1) The actual or relative potential for abuse;
- 6 (2) The scientific evidence of its pharmacological effect, if known;
- 7 (3) The state of current scientific knowledge regarding the substance;
- 8 (4) The history and current pattern of abuse;
- 9 (5) The scope, duration, and significance of abuse;
- 10 (6) The risk to the public health;
- 11 (7) The potential of the substance to produce psychic or physiological
12 dependence liability; and
- 13 (8) Whether the substance is an immediate precursor of a substance
14 already controlled under this chapter.

15 2. After considering the factors enumerated in subsection 1 of this section
16 the department of health and senior services shall make findings with respect
17 thereto and issue a rule controlling the substance if it finds the substance has a
18 potential for abuse.

EXPLANATION—Matter enclosed in bold-faced brackets [thus] in this bill is not enacted and is intended to be omitted in the law.

19 3. If the department of health and senior services designates a substance
20 as an immediate precursor, substances which are precursors of the controlled
21 precursor shall not be subject to control solely because they are precursors of the
22 controlled precursor.

23 4. If any substance is designated, rescheduled, or deleted as a controlled
24 substance under federal law and notice thereof is given to the department of
25 health and senior services, the department of health and senior services shall
26 similarly control the substance under this chapter [after the expiration of] **and**
27 **shall submit emergency rules to the secretary of state under section**
28 **536.025 within** thirty days [from] of publication in the federal register of a final
29 order designating a substance as a controlled substance or rescheduling or
30 deleting a substance, unless within that thirty-day period, the department of
31 health and senior services objects to inclusion, rescheduling, or deletion. In that
32 case, the department of health and senior services shall publish the reasons for
33 objection and afford all interested parties an opportunity to be heard. At the
34 conclusion of the hearing, the department of health and senior services shall
35 publish its decision, which shall be final unless altered by statute. Upon
36 publication of objection to inclusion, rescheduling or deletion under this chapter
37 by the department of health and senior services, control under this chapter is
38 stayed as to the substance in question until the department of health and senior
39 services publishes its decision. **If the department promulgates emergency**
40 **rules under this subsection, such rules may, notwithstanding the**
41 **provisions of subsection 7 of section 536.025, remain in effect until the**
42 **general assembly concludes its next regular session following the**
43 **imposition of any such rules.**

44 5. The department of health and senior services shall exclude any
45 nonnarcotic substance from a schedule if such substance may, under the federal
46 Food, Drug, and Cosmetic Act and the law of this state, be lawfully sold over the
47 counter without a prescription.

48 6. The department of health and senior services shall prepare a list of all
49 drugs falling within the purview of controlled substances. Upon preparation, a
50 copy of the list shall be filed in the office of the secretary of state.

195.017. 1. The department of health and senior services shall place a
2 substance in Schedule I if it finds that the substance:

- 3 (1) Has high potential for abuse; and
- 4 (2) Has no accepted medical use in treatment in the United States or

5 lacks accepted safety for use in treatment under medical supervision.

6 2. Schedule I:

7 (1) The controlled substances listed in this subsection are included in
8 Schedule I;

9 (2) Any of the following opiates, including their isomers, esters, ethers,
10 salts, and salts of isomers, esters, and ethers, unless specifically excepted,
11 whenever the existence of these isomers, esters, ethers and salts is possible
12 within the specific chemical designation:

13 (a) Acetyl-alpha-methylfentanyl (**N-(1-(1-methyl-2-phenethyl)**
14 **-4-piperidinyl)-N-phenylacetamide**);

15 (b) Acetylmethadol;

16 (c) **AH-7921(3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]**
17 **benzamide**);

18 (d) Allylprodine;

19 [(d)] (e) Alphacetylmethadol (**except levoalphacetylmethadol, also**
20 **known as levo-alpha-acetylmethadol levothadyl acetate or LAAM**);

21 [(e)] (f) Alphameprodine;

22 [(f)] (g) Alphamethadol;

23 [(g)] (h) Alpha-methylfentanyl (**N-1-(alphamethyl-beta-phenyl) ethyl-**
24 **4-piperidyl) propionanilide; 1-(1-methyl-2-phenylethyl)-4 ((N-**
25 **propanilido) piperidine)**;

26 [(h)] (i) Alpha-methylthiofentanyl (**N-(1-methyl-2-(2-thienyl) ethyl-4-**
27 **piperidinyl)-N-phenylpropanamide**);

28 [(i)] (j) Benzethidine;

29 [(j)] (k) Betacetylmethadol;

30 [(k)] (l) Beta-hydroxyfentanyl (**N-(1-(2-hydroxy-2-phenethyl)-4-**
31 **piperidinyl)-N-phenylpropanamide**);

32 [(l)] (m) Beta-hydroxy-3-methylfentanyl (**N-(1-(2-hydroxy-2-**
33 **phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide**);

34 [(m)] (n) Betameprodine;

35 [(n)] (o) Betamethadol;

36 [(o)] (p) Betaprodine;

37 [(p)] (q) Clonitazene;

38 [(q)] (r) Dextromoramide;

39 [(r)] (s) Diampromide;

40 [(s)] (t) Diethylthiambutene;

- 41 [(t)] (u) DifenoXin;
- 42 [(u)] (v) Dimenoxadol;
- 43 [(v)] (w) Dimepheptanol;
- 44 [(w)] (x) Dimethylthiambutene;
- 45 [(x)] (y) Dioxaphetyl butyrate;
- 46 [(y)] (z) Dipipanone;
- 47 [(z)] (aa) Ethylmethylthiambutene;
- 48 [(aa)] (bb) Etonitazene;
- 49 [(bb)] (cc) EtoXeridine;
- 50 [(cc)] (dd) Furethidine;
- 51 [(dd)] (ee) HydroXypethidine;
- 52 [(ee)] (ff) Ketobemidone;
- 53 [(ff)] (gg) Levomoramide;
- 54 [(gg)] (hh) Levophenacylmorphane;
- 55 [(hh)] (ii) 3-Methylfentanyl (**N-(3-methyl-1-(2-phenylethyl)-4-**
- 56 **piperidyl)-N-phenylpropanamide**), its optical and geometric isomers,
- 57 **salts and salts of isomers**;
- 58 [(ii)] (jj) 3-Methylthiofentanyl (**N-((3-methyl-1-(2-thienyl)ethyl-4-**
- 59 **piperidinyl)-N-phenylpropanamide**);
- 60 [(jj)] (kk) Morpheridine;
- 61 [(kk)] (ll) MPPP (**1-methyl-4-phenyl-4-propionoxypiperidine**);
- 62 [(ll)] (mm) Noracymethadol;
- 63 [(mm)] (nn) Norlevorphanol;
- 64 [(nn)] (oo) Normethadone;
- 65 [(oo)] (pp) Norpipanone;
- 66 [(pp)] (qq) Para-fluorofentanyl (**N-(4-fluorophenyl)-N-(1-(2-**
- 67 **phenethyl)-4-piperidinyl) propanamide**);
- 68 [(qq)] (rr) PEPAP (**1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine**);
- 69 [(rr)] (ss) Phenadoxone;
- 70 [(ss)] (tt) Phenampromide;
- 71 [(tt)] (uu) Phenomorphan;
- 72 [(uu)] (vv) Phenoperidine;
- 73 [(vv)] (ww) Piritramide;
- 74 [(ww)] (xx) Proheptazine;
- 75 [(xx)] (yy) Properidine;
- 76 [(yy)] (zz) Propiram;

- 77 [(zz)] **(aaa)** Racemoramide;
- 78 [(aaa)] **(bbb)** Thiofentanyl **(N-phenyl-N-(1-(2-thienyl)ethyl-4-**
- 79 **piperidinyl)-propanamide;**
- 80 [(bbb)] **(ccc)** Tilidine;
- 81 [(ccc)] **(ddd)** Trimeperidine;
- 82 (3) Any of the following opium derivatives, their salts, isomers and salts
- 83 of isomers unless specifically excepted, whenever the existence of these salts,
- 84 isomers and salts of isomers is possible within the specific chemical designation:
- 85 (a) Acetorphine;
- 86 (b) Acetyldihydrocodeine;
- 87 (c) Benzylmorphine;
- 88 (d) Codeine methylbromide;
- 89 (e) Codeine-N-Oxide;
- 90 (f) Cyprenorphine;
- 91 (g) Desomorphine;
- 92 (h) Dihydromorphine;
- 93 (i) Drotebanol;
- 94 (j) Etorphine (except hydrochloride salt);
- 95 (k) Heroin;
- 96 (l) Hydromorphanol;
- 97 (m) Methyldesorphine;
- 98 (n) Methyldihydromorphine;
- 99 (o) Morphine methylbromide;
- 100 (p) Morphine methylsulfonate;
- 101 (q) Morphine-N-Oxide;
- 102 (r) Myrophine;
- 103 (s) Nicocodeine;
- 104 (t) Nicomorphine;
- 105 (u) Normorphine;
- 106 (v) Pholcodine;
- 107 (w) Thebacon;
- 108 (4) Any material, compound, mixture or preparation which contains any
- 109 quantity of the following hallucinogenic substances, their salts, isomers and salts
- 110 of isomers, unless specifically excepted, whenever the existence of these salts,
- 111 isomers, and salts of isomers is possible within the specific chemical designation:
- 112 (a) **Alpha-ethyltryptamine;**

- 113 **(b)** 4-bromo-2, 5-dimethoxyamphetamine;
114 **[(b)] (c)** 4-bromo-2, 5-dimethoxyphenethylamine;
115 **[(c)] (d)** 2,5-dimethoxyamphetamine;
116 **[(d)] (e)** 2,5-dimethoxy-4-ethylamphetamine;
117 **[(e)] (f)** 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
118 **[(f)] (g)** **2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine;**
119 **(h)** **2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine;**
120 **(i)** **2-(2,5-Dimethoxy-4-methylphenyl) ethanamine;**
121 **(j)** **2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine;**
122 **(k)** **2-(2,5-Dimethoxyphenyl) ethanamine;**
123 **(l)** **2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine;**
124 **(m)** **2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine;**
125 **(n)** **2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine;**
126 **(o)** **2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine;**
127 **(p)** 4-methoxyamphetamine;
128 **[(g)] (q)** 5-methoxy-3,4-methylenedioxyamphetamine;
129 **[(h)] (r)** 4-methyl-2, 5-dimethoxyamphetamine;
130 **[(i)] (s)** 3,4-methylenedioxyamphetamine;
131 **[(j)] (t)** 3,4-methylenedioxymethamphetamine;
132 **[(k)] (u)** 3,4-methylenedioxy-N-ethylamphetamine;
133 **[(l)] (v)** N-hydroxy-3, 4-methylenedioxyamphetamine;
134 **[(m)] (w)** 3,4,5-trimethoxyamphetamine;
135 **[(n)] (x)** 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine[, its isomers,
136 salts, and salts of isomers];
137 **[(o)** Alpha-ethyltryptamine;
138 **(p)] (y)** Alpha-methyltryptamine;
139 **[(q)] (z)** Bufotenine;
140 **[(r)] (aa)** Diethyltryptamine;
141 **[(s)] (bb)** Dimethyltryptamine;
142 **[(t)] (cc)** 5-methoxy-N,N-diisopropyltryptamine;
143 **[(u)] (dd)** Ibogaine;
144 **[(v)] (ee)** Lysergic acid diethylamide;
145 **[(w)] (ff)** Marijuana or marihuana;
146 **[(x)] (gg)** Mescaline;
147 **[(y)] (hh)** Parahexyl;
148 **[(z)] (ii)** Peyote, to include all parts of the plant presently classified

149 botanically as *Lophophora* [Williamsil] **williamsii** Lemaire, whether growing or
150 not; the seeds thereof; any extract from any part of such plant; and every
151 compound, manufacture, salt, derivative, mixture or preparation of the plant, its
152 seed or extracts;

153 [(aa)] **(jj)** N-ethyl-3-piperidyl benzilate;

154 [(bb)] **(kk)** N-methyl-3-piperidyl benzilate;

155 [(cc)] **(ll)** Psilocybin;

156 [(dd)] **(mm)** Psilocyn;

157 [(ee)] **(nn)** Tetrahydrocannabinols naturally contained in a plant of the
158 genus *Cannabis* (*cannabis* plant), as well as synthetic equivalents of the
159 substances contained in the *cannabis* plant, or in the resinous extractives of such
160 plant, or synthetic substances, derivatives[,] and their isomers, **or both**, with
161 similar chemical structure and pharmacological activity to those substances
162 contained in the plant, such as the following:

163 a. 1 cis or trans tetrahydrocannabinol[,] and their optical isomers;

164 b. 6 cis or trans tetrahydrocannabinol[,] and their optical isomers;

165 c. 3,4 cis or trans tetrahydrocannabinol[,] and their optical isomers;

166 d. Any compounds of these structures, regardless of numerical designation
167 of atomic positions covered;

168 [(ff)] **(oo)** Ethylamine analog of phencyclidine;

169 [(gg)] **(pp)** Pyrrolidine analog of phencyclidine;

170 [(hh)] **(qq)** Thiophene analog of phencyclidine;

171 [(ii)] **(rr)** [1-[1-(2-thienyl)cyclohexyl]pyrrolidine] **1-(1-(2-**
172 **thienyl)cyclohexyl) pyrrolidine;**

173 [(jj)] **(ss)** *Salvia divinorum*;

174 [(kk)] **(tt)** *Salvinorin A*;

175 [(ll)] **(uu)** Synthetic cannabinoids:

176 a. Any compound structurally derived from 3-(1-naphthoyl)indole or
177 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the
178 indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
179 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not
180 further substituted in the indole ring to any extent, whether or not substituted
181 in the naphthyl ring to any extent. Including, but not limited to:

182 (i) **AM2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;**

183 (ii) **JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;**

184 [(ii)] (iii) **JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;**

- 185 [(iii)] (iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
186 [(iv)] (v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
187 [(v)] (vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
188 [(vi)] (vii) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
189 [(vii)] (viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-
190 naphthoyl)indole;
191 [(viii)] (ix) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;
192 [(ix)] (x) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
193 [(x)] (xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
194 [(xi)] (xii) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
195 [(xii)] (xiii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
196 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by
197 substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
198 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
199 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole
200 ring to any extent, whether or not substituted in the naphthyl ring to any extent;
201 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene
202 by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl,
203 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
204 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene
205 ring to any extent, whether or not substituted in the naphthyl ring to any extent;
206 d. Any compound structurally derived from 3-phenylacetylindole by
207 substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl,
208 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
209 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
210 ring to any extent, whether or not substituted in the phenyl ring to any
211 extent. Including, but not limited to:
212 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
213 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
214 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
215 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
216 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
217 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol
218 by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl,
219 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
220 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring

221 to any extent. Including, but not limited to:

222 (i) CP 47, 497 [&] and homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-
223 5-(2-methyloctan-2-yl)phenol), where side chain n=5, and homologues where side
224 chain n=4,6, or 7;

225 f. Any compound containing a 3-(benzoyl)indole structure with
226 substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl,
227 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
228 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
229 ring to any extent and whether or not substituted in the phenyl ring to any
230 extent. Including, but not limited to:

231 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;

232 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (**SR-19 and RCS-4**);

233 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-
234 [(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]
235 acetate;

236 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-
237 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

238 i. HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,
239 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

240 j. [CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-
241 phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

242 k.] Dimethylheptylpyran, or DMHP;

243 (5) Any material, compound, mixture or preparation containing any
244 quantity of the following substances having a depressant effect on the central
245 nervous system, including their salts, isomers and salts of isomers whenever the
246 existence of these salts, isomers and salts of isomers is possible within the
247 specific chemical designation:

248 (a) Gamma-hydroxybutyric acid;

249 (b) Mecloqualone;

250 (c) Methaqualone;

251 (6) Any material, compound, mixture or preparation containing any
252 quantity of the following substances having a stimulant effect on the central
253 nervous system, including their salts, isomers and salts of isomers:

254 (a) Aminorex;

255 (b) N-benzylpiperazine;

256 (c) Cathinone;

- 257 (d) Fenethylamine;
- 258 (e) 3-Fluoromethcathinone;
- 259 (f) 4-Fluoromethcathinone;
- 260 (g) Mephedrone, or 4-methylmethcathinone;
- 261 (h) Methcathinone;
- 262 (i) 4-methoxymethcathinone;
- 263 (j) [(+,-)]cis-4-methylaminorex [(+,-)]cis-4,5-dihydro-4-methyl-5-
- 264 phenyl-2-oxazolamine);
- 265 (k) Methylenedioxypropylone, MDPV, or
- 266 (1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone);
- 267 (l) Methylone, or 3,4-Methylenedioxymethcathinone;
- 268 (m) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP;
- 269 (n) N-ethylamphetamine;
- 270 (o) N,N-dimethylamphetamine;
- 271 **(p) Quinolin-8-yl 1-pentyl-1*H*-indole-3-carboxylate (PB-22;**
- 272 **QUPIC);**
- 273 **(q) Quinolin-8-yl 1-(5-fluoropentyl)-1*H*-indole-3-carboxylate (5-**
- 274 **fluoro-PB-22; 5F-PB-22);**
- 275 **(r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-**
- 276 **indazole-3-carboxamide (AB-FUBINACA);**
- 277 **(s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-**
- 278 **indazole-3-carboxamide (ADB-PINACA);**
- 279 (7) A temporary listing of substances subject to emergency scheduling
- 280 under federal law shall include any material, compound, mixture or preparation
- 281 which contains any quantity of the following substances:
- 282 (a) [N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its
- 283 optical isomers, salts and salts of isomers;
- 284 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
- 285 (thenylfentanyl), its optical isomers, salts and salts of isomers;] **(1-pentyl-1*H*-**
- 286 **indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, its optical,**
- 287 **positional, and geometric isomers, salts, and salts of isomers;**
- 288 **(b) [1-(5-fluoro-pentyl)-1*H*-indol-3-yl](2,2,3,3-**
- 289 **tetramethylcyclopropyl)methanone, its optical, positional, and**
- 290 **geometric isomers, salts, and salts of isomers;**
- 291 **(c) N-(1-adamantyl)-1-pentyl-1*H*-indazole-3-carboxamide, its**
- 292 **optical, positional, and geometric isomers, salts, and salts of isomers;**

293 (d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
294 methoxybenzyl)ethanamine, its optical, positional, and geometric
295 isomers, salts, and salts of isomers;

296 (e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
297 methoxybenzyl)ethanamine, its optical, positional, and geometric
298 isomers, salts, and salts of isomers;

299 (f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
300 methoxybenzyl)ethanamine, its optical, positional, and geometric
301 isomers, salts, and salts of isomers;

302 (g) 4-methyl-N-ethylcathinone, its optical, positional, and
303 geometric isomers, salts, and salts of isomers;

304 (h) 4-methyl-alpha-pyrrolidinopropiophenone, its optical,
305 positional, and geometric isomers, salts, and salts of isomers;

306 (i) alpha-pyrrolidinopentiophenone, its optical, positional, and
307 geometric isomers, salts, and salts of isomers;

308 (j) Butylone, its optical, positional, and geometric isomers, salts,
309 and salts of isomers;

310 (k) Pentedrone, its optical, positional, and geometric isomers,
311 salts, and salts of isomers;

312 (l) Pentylone, its optical, positional, and geometric isomers, salts,
313 and salts of isomers;

314 (m) Naphyrone, its optical, positional, and geometric isomers,
315 salts, and salts of isomers;

316 (n) alpha-pyrrolidinobutiophenone, its optical, positional, and
317 geometric isomers, salts, and salts of isomers;

318 (o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-
319 indazole-3-carboxamide, its optical, positional, and geometric isomers,
320 salts, and salts of isomers;

321 (p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-
322 carboxamide, its optical, positional, and geometric isomers, salts, and
323 salts of isomers;

324 (q) [1-(5-fluoropentyl)-1*H*-indazole-3-yl](naphthalen-1-
325 yl)methanone, its optical, positional, and geometric isomers, salts, and
326 salts of isomers;

327 (r) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its
328 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers;

329 (s) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-4-yl]-N-

330 **phenylpropionamide, its isomers, esters, ethers, salts, and salts of**
331 **isomers, esters, and ethers;**

332 (t) **N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical,**
333 **positional, and geometric isomers, salts, and salts of isomers;**

334 (u) **N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-**
335 **(cyclohexylmethyl)-1*H*-indazole-3-carboxamide, its optical, positional,**
336 **and geometric isomers, salts, and salts of isomers;**

337 (v) **3, 4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-**
338 **methylbenzamide;**

339 (w) **N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide;**

340 (8) Khat, to include all parts of the plant presently classified botanically
341 as *catha edulis*, whether growing or not; the seeds thereof; any extract from any
342 part of such plant; and every compound, manufacture, salt, derivative, mixture,
343 or preparation of the plant, its seed or extracts.

344 3. The department of health and senior services shall place a substance
345 in Schedule II if it finds that:

346 (1) The substance has high potential for abuse;

347 (2) The substance has currently accepted medical use in treatment in the
348 United States, or currently accepted medical use with severe restrictions; and

349 (3) The abuse of the substance may lead to severe psychic or physical
350 dependence.

351 4. The controlled substances listed in this subsection are included in
352 Schedule II:

353 (1) Any of the following substances whether produced directly or indirectly
354 by extraction from substances of vegetable origin, or independently by means of
355 chemical synthesis, or by combination of extraction and chemical synthesis:

356 (a) Opium and opiate; and any salt, compound, derivative or preparation
357 of opium or opiate, excluding apomorphine, thebaine-derived butorphanol,
358 dextrorphan, nalbuphine, nalmefene, **naloxegol**, naloxone, and naltrexone, and
359 their respective salts but including the following:

360 a. Raw opium;

361 b. Opium extracts;

362 c. Opium fluid;

363 d. Powdered opium;

364 e. Granulated opium;

365 f. Tincture of opium;

- 366 g. Codeine;
- 367 h. **Dihydroetorphine;**
- 368 i. Ethylmorphine;
- 369 [i.] j. Etorphine hydrochloride;
- 370 [j.] k. Hydrocodone;
- 371 [k.] l. Hydromorphone;
- 372 [l.] m. Metopon;
- 373 [m.] n. Morphine;
- 374 [n.] o. **Oripavine;**
- 375 p. Oxycodone;
- 376 [o.] q. Oxymorphone;
- 377 [p.] r. Thebaine;
- 378 (b) Any salt, compound, derivative, or preparation thereof which is
- 379 chemically equivalent or identical with any of the substances referred to in this
- 380 subdivision, but not including the isoquinoline alkaloids of opium;
- 381 (c) Opium poppy and poppy straw;
- 382 (d) Coca leaves and any salt, compound, derivative, or preparation of coca
- 383 leaves, and any salt, compound, derivative, or preparation thereof which is
- 384 chemically equivalent or identical with any of these substances, but not including
- 385 **the following:**
- 386 a. Decocainized coca leaves or extractions **of coca leaves**, which
- 387 **extractions** do not contain cocaine or ecgonine; **or**
- 388 **b. Ioflupane;**
- 389 (e) Concentrate of poppy straw (the crude extract of poppy straw in either
- 390 liquid, solid or powder form which contains the phenanthrene alkaloids of the
- 391 opium poppy);
- 392 (2) Any of the following opiates, including their isomers, esters, ethers,
- 393 salts, and salts of isomers, whenever the existence of these isomers, esters,
- 394 ethers, and salts is possible within the specific chemical designation, dextrorphan
- 395 and levopropoxyphene excepted:
- 396 (a) Alfentanil;
- 397 (b) Alphaprodine;
- 398 (c) Anileridine;
- 399 (d) Bezitramide;
- 400 (e) Bulk dextropropoxyphene;
- 401 (f) Carfentanil;

- 402 (g) Dihydrocodeine;
- 403 (h) Diphenoxylate;
- 404 (i) Fentanyl;
- 405 (j) Isomethadone;
- 406 (k) Levo-alphaacetylmethadol;
- 407 (l) Levomethorphan;
- 408 (m) Levorphanol;
- 409 (n) Metazocine;
- 410 (o) Methadone;
- 411 (p) [Meperidine];
- 412 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl
- 413 butane;
- 414 [(r)] (q) Moramide-Intermediate, 2-methyl-3-morpholino-1,
- 415 1-diphenylpropane-carboxylic acid;
- 416 [(s)] (r) Pethidine (meperidine);
- 417 [(t)] (s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 418 [(u)] (t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 419 [(v)] (u) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic
- 420 acid;
- 421 [(w)] (v) Phenazocine;
- 422 [(x)] (w) Piminodine;
- 423 [(y)] (x) Racemethorphan;
- 424 [(z)] (y) Racemorphan;
- 425 [(aa)] (z) Remifentanyl;
- 426 [(bb)] (aa) Sufentanyl;
- 427 [(cc)] (bb) Tapentadol;
- 428 (cc) **Thiafentanyl;**
- 429 (3) Any material, compound, mixture, or preparation which contains any
- 430 quantity of the following substances having a stimulant effect on the central
- 431 nervous system:
- 432 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 433 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 434 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 435 (d) Phenmetrazine and its salts;
- 436 (e) Methylphenidate;
- 437 (4) Any material, compound, mixture, or preparation which contains any

438 quantity of the following substances having a depressant effect on the central
439 nervous system, including its salts, isomers, and salts of isomers whenever the
440 existence of those salts, isomers, and salts of isomers is possible within the specific
441 chemical designation:

- 442 (a) Amobarbital;
- 443 (b) Glutethimide;
- 444 (c) Pentobarbital;
- 445 (d) Phencyclidine;
- 446 (e) Secobarbital;
- 447 (5) Any material or compound which contains any quantity of nabilone;
- 448 (6) Any material, compound, mixture, or preparation which contains any

449 quantity of the following substances:

450 (a) Immediate precursor to amphetamine and methamphetamine:
451 Phenylacetone;

452 (b) Immediate precursors to phencyclidine (PCP):

453 a. 1-phenylcyclohexylamine;

454 b. 1-piperidinocyclohexanecarbonitrile (PCC);

455 **(c) Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-**
456 **piperidine (ANPP);**

457 (7) Any material, compound, mixture, or preparation which contains any
458 quantity of the following alkyl nitrites:

459 (a) Amyl nitrite;

460 (b) Butyl nitrite.

461 5. The department of health and senior services shall place a substance in
462 Schedule III if it finds that:

463 (1) The substance has a potential for abuse less than the substances listed
464 in Schedules I and II;

465 (2) The substance has currently accepted medical use in treatment in the
466 United States; and

467 (3) Abuse of the substance may lead to moderate or low physical
468 dependence or high psychological dependence.

469 6. The controlled substances listed in this subsection are included in
470 Schedule III:

471 (1) Any material, compound, mixture, or preparation which contains any
472 quantity of the following substances having a potential for abuse associated with
473 a stimulant effect on the central nervous system:

- 474 (a) Benzphetamine;
- 475 (b) Chlorphentermine;
- 476 (c) Clortermine;
- 477 (d) Phendimetrazine;
- 478 (2) Any material, compound, mixture or preparation which contains any
- 479 quantity or salt of the following substances or salts having a depressant effect on
- 480 the central nervous system:
- 481 (a) Any material, compound, mixture or preparation which contains any
- 482 quantity or salt of the following substances combined with one or more active
- 483 medicinal ingredients:
- 484 a. Amobarbital;
- 485 b. Secobarbital;
- 486 c. Pentobarbital;
- 487 (b) Any suppository dosage form containing any quantity or salt of the
- 488 following:
- 489 a. Amobarbital;
- 490 b. Secobarbital;
- 491 c. Pentobarbital;
- 492 (c) Any substance which contains any quantity of a derivative of barbituric
- 493 acid or its salt;
- 494 (d) Chlorhexadol;
- 495 (e) Embutramide;
- 496 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers
- 497 contained in a drug product for which an application has been approved under
- 498 Section 505 of the federal Food, Drug, and Cosmetic Act;
- 499 (g) Ketamine, its salts, isomers, and salts of isomers;
- 500 (h) Lysergic acid;
- 501 (i) Lysergic acid amide;
- 502 (j) Methyprylon;
- 503 (k) **Perampanel, and its salts, isomers, and salts of isomers;**
- 504 **(l) Sulfondiethylmethane;**
- 505 **[(l)] (m) Sulfonethylmethane;**
- 506 **[(m)] (n) Sulfonmethane;**
- 507 **[(n)] (o) Tiletamine and zolazepam or any salt thereof;**
- 508 (3) Nalorphine;
- 509 (4) Any material, compound, mixture, or preparation containing limited

510 quantities of any of the following narcotic drugs or their salts:

511 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not
512 more than ninety milligrams per dosage unit, with an equal or greater quantity of
513 an isoquinoline alkaloid of opium;

514 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not
515 more than ninety milligrams per dosage unit, with one or more active, nonnarcotic
516 ingredients in recognized therapeutic amounts;

517 (c) [Not more than three hundred milligrams of hydrocodone per one
518 hundred milliliters or not more than fifteen milligrams per dosage unit, with a
519 fourfold or greater quantity of an isoquinoline alkaloid of opium;

520 (d) Not more than three hundred milligrams of hydrocodone per one
521 hundred milliliters or not more than fifteen milligrams per dosage unit, with one
522 or more active nonnarcotic ingredients in recognized therapeutic amounts;

523 (e)] Not more than 1.8 grams of dihydrocodeine per one hundred milliliters
524 or not more than ninety milligrams per dosage unit, with one or more active,
525 nonnarcotic ingredients in recognized therapeutic amounts;

526 [(f) (d) Not more than three hundred milligrams of ethylmorphine per one
527 hundred milliliters or not more than fifteen milligrams per dosage unit, with one
528 or more active, nonnarcotic ingredients in recognized therapeutic amounts;

529 [(g) (e) Not more than five hundred milligrams of opium per one hundred
530 milliliters or per one hundred grams or not more than twenty-five milligrams per
531 dosage unit, with one or more active, nonnarcotic ingredients in recognized
532 therapeutic amounts;

533 [(h) (f) Not more than fifty milligrams of morphine per one hundred
534 milliliters or per one hundred grams, with one or more active, nonnarcotic
535 ingredients in recognized therapeutic amounts;

536 (5) Any material, compound, mixture, or preparation containing any of the
537 following narcotic drugs or their salts[, as set forth in subdivision (6) of this
538 subsection;]: Buprenorphine;

539 (6) Anabolic steroids. Any drug or hormonal substance, chemically and
540 pharmacologically related to testosterone (other than estrogens, progestins,
541 corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except
542 an anabolic steroid which is expressly intended for administration through
543 implants to cattle or other nonhuman species and which has been approved by the
544 Secretary of Health and Human Services for that administration. If any person
545 prescribes, dispenses, or distributes such steroid for human use, such person shall

546 be considered to have prescribed, dispensed, or distributed an anabolic steroid
547 within the meaning of this subdivision. Unless specifically excepted or unless
548 listed in another schedule, any material, compound, mixture or preparation
549 containing any quantity of the following substances, including its salts, esters and
550 ethers:

- 551 (a) [3 β ,17-dihydroxy-5 α -androstande] **3 β ,17 β -dihydroxy-5 α -androstande**;
552 (b) 3 α ,17 β -dihydroxy-5 α -androstande;
553 (c) 5 α -androstand-3,17-dione;
554 (d) 1-androstenediol (3 β ,17 β -dihydroxy-5 α -androstand-1-ene);
555 (e) 1-androstenediol (3 α ,17 β -dihydroxy-5 α -androstand-1-ene);
556 (f) 4-androstenediol (3 β ,17 β -dihydroxy-androstand-4-ene);
557 (g) 5-androstenediol (3 β ,17 β -dihydroxy-androstand-5-ene);
558 (h) 1-androstenedione ([5 α]-androstand-1-en-3,17-dione);
559 (i) 4-androstenedione (androstand-4-en-3,17-dione);
560 (j) 5-androstenedione (androstand-5-en-3,17-dione);
561 (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandrostand-4-en-3-one);
562 (l) Boldenone (17 β -hydroxyandrostand-1,4,-diene-3-one);
563 (m) Boldione (**androstand-1,4-diene-3,17-dione**);
564 (n) Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandrostand-4-en-3-one);
565 (o) Clostebol (4-chloro-17 β -hydroxyandrostand-4-en-3-one);
566 (p) Dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methyl-
567 androstand-1,4-dien-3-one);
568 (q) Desoxymethyltestosterone (**17 α -methyl-5 α -androstand-2-en-17 β -ol**)
569 (**a.k.a. madol**);
570 (r) [Δ 1-dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -androstand-
571 1-en-3-one)] **Dihydrotestosterone (4-Dihydrotestosterone) (17 β -hydroxy-**
572 **androstand-3-one)**;
573 (s) [4-dihydrotestosterone (17 β -hydroxy-androstand-3-one);
574 (t)] Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstand-3-one);
575 [(u)] (t) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
576 [(v)] (u) Fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrostand-4-
577 en-3-one);
578 [(w)] (v) Formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrostand-1,4-
579 dien-3-one);
580 [(x)] (w) Furazabol (17 α -methyl-17 β -hydroxyandrostando[2,3-c]-furazan);
581 [(y)] (x) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;

- 582 [(z)] (y) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
- 583 [(aa)] (z) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
- 584 [(bb)] (aa) [Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one)]
- 585 **Mestanolone (17 α -methyl-17 β -hydroxy-5 α -androstan-3-one);**
- 586 [(cc)] (bb) [Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one)]
- 587 **Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);**
- 588 [(dd)] (cc) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
- 589 [(ee)] (dd) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
- 590 [(ff)] (ee) **Methasterone (2 α ,17 α -dimethyl-5 α -androstan-17 β -ol-3-one);**
- 591 (ff) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
- 592 (gg) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstan-3-one);
- 593 (hh) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstan-3-one);
- 594 (ii) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene);
- 595 (jj) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -
- 596 hydroxyestr-4-en-3-one);
- 597 (kk) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
- 598 (ll) [Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9,11-trien-3-one)]
- 599 **Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9,11-trien-3-one);**
- 600 (mm) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
- 601 (nn) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
- 602 (oo) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -
- 603 androst-1-en-3-one) (a.k.a. '17- α -methyl-1-testosterone');
- 604 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
- 605 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
- 606 (rr) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
- 607 (ss) 19-nor-4,9(10)-androstadienedione (**estra-4,9(10)-diene-3,17-dione**);
- 608 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
- 609 (uu) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
- 610 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 611 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 612 (xx) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
- 613 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
- 614 (zz) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
- 615 (aaa) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
- 616 (bbb) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
- 617 (ccc) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);

618 (ddd) Oxymethalone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-
619 androstan-3-one);
620 (eee) **Prostanozolol (17 β -hydroxy-5 α -androstan-3-one)[3,2-c]pyrazole);**
621 **(fff) Stanolone (Δ 1-dihydrotestosterone (a.k.a. 1-testosterone)(17 β -**
622 **hydroxy-5 α -androst-1-en-3-one));**
623 **(ggg) Stanozolol (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-**
624 **pyrazole);**
625 [(fff)] **(hhh) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);**
626 [(ggg)] **(iii) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-**
627 **oic acid lactone);**
628 [(hhh)] **(jjj) Testosterone (17 β -hydroxyandrost-4-en-3-one);**
629 [(iii)] **(kkk) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-**
630 **trien-3-one);**
631 [(jjj)] **(III) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);**
632 [(kkk)] **(mmm) Any salt, ester, or ether of a drug or substance described**
633 **or listed in this subdivision, except an anabolic steroid which is expressly intended**
634 **for administration through implants to cattle or other nonhuman species and which**
635 **has been approved by the Secretary of Health and Human Services for that**
636 **administration;**
637 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin
638 capsule in a United States Food and Drug Administration approved drug product;
639 (8) The department of health and senior services may except by rule any
640 compound, mixture, or preparation containing any stimulant or depressant
641 substance listed in subdivisions (1) and (2) of this subsection from the application
642 of all or any part of sections 195.010 to 195.320 if the compound, mixture, or
643 preparation contains one or more active medicinal ingredients not having a
644 stimulant or depressant effect on the central nervous system, and if the admixtures
645 are included therein in combinations, quantity, proportion, or concentration that
646 vitiate the potential for abuse of the substances which have a stimulant or
647 depressant effect on the central nervous system.
648 7. The department of health and senior services shall place a substance in
649 Schedule IV if it finds that:
650 (1) The substance has a low potential for abuse relative to substances in
651 Schedule III;
652 (2) The substance has currently accepted medical use in treatment in the
653 United States; and

654 (3) Abuse of the substance may lead to limited physical dependence or
655 psychological dependence relative to the substances in Schedule III.

656 8. The controlled substances listed in this subsection are included in
657 Schedule IV:

658 (1) Any material, compound, mixture, or preparation containing any of the
659 following narcotic drugs or their salts calculated as the free anhydrous base or
660 alkaloid, in limited quantities as set forth below:

661 (a) Not more than one milligram of difenoxin and not less than twenty-five
662 micrograms of atropine sulfate per dosage unit;

663 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-
664 3-methyl-2-propionoxybutane);

665 (c) **2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
666 salts, optical, and geometric isomers, and salts of these isomers (including
667 tramadol);**

668 (d) Any of the following limited quantities of narcotic drugs or their salts,
669 which shall include one or more nonnarcotic active medicinal ingredients in
670 sufficient proportion to confer upon the compound, mixture or preparation valuable
671 medicinal qualities other than those possessed by the narcotic drug alone:

672 a. Not more than two hundred milligrams of codeine per one hundred
673 milliliters or per one hundred grams;

674 b. Not more than one hundred milligrams of dihydrocodeine per one
675 hundred milliliters or per one hundred grams;

676 c. Not more than one hundred milligrams of ethylmorphine per one
677 hundred milliliters or per one hundred grams;

678 (2) Any material, compound, mixture or preparation containing any
679 quantity of the following substances, including their salts, isomers, and salts of
680 isomers whenever the existence of those salts, isomers, and salts of isomers is
681 possible within the specific chemical designation:

682 (a) **Alfaxalone;**

683 (b) Alprazolam;

684 [(b)] (c) Barbitol;

685 [(c)] (d) Bromazepam;

686 [(d)] (e) Camazepam;

687 [(e)] (f) **Carisoprodol;**

688 (g) Chloral betaine;

689 [(f)] (h) Chloral hydrate;

690 [(g)] (i) Chlordiazepoxide;
691 [(h)] (j) Clobazam;
692 [(i)] (k) Clonazepam;
693 [(j)] (l) Clorazepate;
694 [(k)] (m) Clotiazepam;
695 [(l)] (n) Cloxazolam;
696 [(m)] (o) Delorazepam;
697 [(n)] (p) Diazepam;
698 [(o)] (q) Dichloralphenazone;
699 [(p)] (r) Estazolam;
700 [(q)] (s) Ethchlorvynol;
701 [(r)] (t) Ethinamate;
702 [(s)] (u) Ethyl loflazepate;
703 [(t)] (v) Fludiazepam;
704 [(u)] (w) Flunitrazepam;
705 [(v)] (x) Flurazepam;
706 [(w)] (y) Fospropofol;
707 [(x)] (z) Halazepam;
708 [(y)] (aa) Haloxazolam;
709 [(z)] (bb) Ketazolam;
710 [(aa)] (cc) Loprazolam;
711 [(bb)] (dd) Lorazepam;
712 [(cc)] (ee) Lormetazepam;
713 [(dd)] (ff) Mebutamate;
714 [(ee)] (gg) Medazepam;
715 [(ff)] (hh) Meprobamate;
716 [(gg)] (ii) Methohexital;
717 [(hh)] (jj) Methylphenobarbital (mephobarbital);
718 [(ii)] (kk) Midazolam;
719 [(jj)] (ll) Nimetazepam;
720 [(kk)] (mm) Nitrazepam;
721 [(ll)] (nn) Nordiazepam;
722 [(mm)] (oo) Oxazepam;
723 [(nn)] (pp) Oxazolam;
724 [(oo)] (qq) Paraldehyde;
725 [(pp)] (rr) Petrichloral;

726 [(qq)] (ss) Phenobarbital;

727 [(rr)] (tt) Pinazepam;

728 [(ss)] (uu) Prazepam;

729 [(tt)] (vv) Quazepam;

730 [(uu)] (ww) **Suvorexant**;

731 (xx) Temazepam;

732 [(vv)] (yy) Tetrazepam;

733 [(ww)] (zz) Triazolam;

734 [(xx)] (aaa) Zaleplon;

735 [(yy)] (bbb) Zolpidem;

736 [(zz)] (ccc) Zopiclone;

737 (3) Any material, compound, mixture, or preparation which contains any
738 quantity of the following substance, including its salts, isomers and salts of isomers
739 whenever the existence of such salts, isomers and salts of isomers is possible:
740 fenfluramine;

741 (4) **Any material, compound, mixture, or preparation which**
742 **contains any quantity of the following substances, including its salts,**
743 **isomers, and salts of isomers, whenever the existence of such salts,**
744 **isomers, and salts of isomers is possible: Lorcaserin;**

745 (5) Any material, compound, mixture or preparation containing any
746 quantity of the following substances having a stimulant effect on the central
747 nervous system, including their salts, isomers and salts of isomers:

748 (a) Cathine ((+)-norpseudoephedrine);

749 (b) Diethylpropion;

750 (c) Fencamfamin;

751 (d) Fenproporex;

752 (e) Mazindol;

753 (f) Mefenorex;

754 (g) Modafinil;

755 (h) Pemoline, including organometallic complexes and chelates thereof;

756 (i) Phentermine;

757 (j) Pipradrol;

758 (k) Sibutramine;

759 (l) [SPA ((-)-1-dimethylamino-1,2-diphenylethane)] SPA

760 **(-)-1-dimethylamino-1,2-diphenylethane;**

761 [(5)] (6) Any material, compound, mixture or preparation containing any
762 quantity of the following substance, including its salts:

763 (a) Butorphanol **(including its optical isomers)**;

764 (b) **Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-2,6-**
765 **dimethylphenyl]-1-oxopropyl] [(1S)-1-(4-phenyl-1 *H*-imidazol-2-**
766 **yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical**
767 **isomers) and its salts, isomers, and salts of isomers;**

768 (c) Pentazocine;

769 [(6)] (7) Ephedrine, its salts, optical isomers and salts of optical isomers,
770 when the substance is the only active medicinal ingredient;

771 [(7)] (8) The department of health and senior services may except by rule
772 any compound, mixture, or preparation containing any depressant substance listed
773 in subdivision (1) of this subsection from the application of all or any part of
774 sections 195.010 to 195.320 and sections 579.015 to 579.086 if the compound,
775 mixture, or preparation contains one or more active medicinal ingredients not
776 having a depressant effect on the central nervous system, and if the admixtures are
777 included therein in combinations, quantity, proportion, or concentration that vitiate
778 the potential for abuse of the substances which have a depressant effect on the
779 central nervous system.

780 9. The department of health and senior services shall place a substance in
781 Schedule V if it finds that:

782 (1) The substance has low potential for abuse relative to the controlled
783 substances listed in Schedule IV;

784 (2) The substance has currently accepted medical use in treatment in the
785 United States; and

786 (3) The substance has limited physical dependence or psychological
787 dependence liability relative to the controlled substances listed in Schedule IV.

788 10. The controlled substances listed in this subsection are included in
789 Schedule V:

790 (1) Any compound, mixture or preparation containing any of the following
791 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in
792 limited quantities as set forth below, which also contains one or more nonnarcotic
793 active medicinal ingredients in sufficient proportion to confer upon the compound,
794 mixture or preparation valuable medicinal qualities other than those possessed by
795 the narcotic drug alone:

796 (a) Not more than two hundred milligrams of codeine per one
797 hundred milliliters or per one hundred grams;

798 (b) Not more than one hundred milligrams of dihydrocodeine per
799 one hundred milliliters or per one hundred grams;

800 (c) Not more than one hundred milligrams of ethylmorphine per
801 one hundred milliliters or per one hundred grams;

802 (d) Not more than two and five-tenths milligrams of diphenoxylate and not
803 less than twenty-five micrograms of atropine sulfate per dosage unit;

804 [(b)] (e) Not more than one hundred milligrams of opium per one hundred
805 milliliters or per one hundred grams;

806 [(c)] (f) Not more than five-tenths milligram of difenoxin and not less than
807 twenty-five micrograms of atropine sulfate per dosage unit;

808 (2) Any material, compound, mixture or preparation which contains any
809 quantity of the following substance having a stimulant effect on the central nervous
810 system including its salts, isomers and salts of isomers: pyrovalerone;

811 (3) Any compound, mixture, or preparation containing any detectable
812 quantity of pseudoephedrine or its salts or optical isomers, or salts of optical
813 isomers or any compound, mixture, or preparation containing any detectable
814 quantity of ephedrine or its salts or optical isomers, or salts of optical isomers;

815 (4) Unless specifically exempted or excluded or unless listed in another
816 schedule, any material, compound, mixture, or preparation which contains any
817 quantity of the following substances having a depressant effect on the central
818 nervous system, including its salts:

819 (a) **Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-**
820 **yl]butanamide) (also referred to as BRV; UCB-34714; Briviact);**

821 (b) **Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-phenyl]-carbamic**
822 **acid ethyl ester];**

823 (c) **Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];**

824 [(b)] (d) **Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].**

825 11. If any compound, mixture, or preparation as specified in subdivision (3)
826 of subsection 10 of this section is dispensed, sold, or distributed in a pharmacy
827 without a prescription:

828 (1) All packages of any compound, mixture, or preparation containing any
829 detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of
830 optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers,
831 shall be offered for sale only from behind a pharmacy counter where the public is

832 not permitted, and only by a registered pharmacist or registered pharmacy
833 technician; and

834 (2) Any person purchasing, receiving or otherwise acquiring any compound,
835 mixture, or preparation containing any detectable quantity of pseudoephedrine, its
836 salts or optical isomers, or salts of optical isomers or ephedrine, its salts or optical
837 isomers, or salts of optical isomers shall be at least eighteen years of age; and

838 (3) The pharmacist, intern pharmacist, or registered pharmacy technician
839 shall require any person, prior to such person's purchasing, receiving or otherwise
840 acquiring such compound, mixture, or preparation to furnish suitable photo
841 identification that is issued by a state or the federal government or a document
842 that, with respect to identification, is considered acceptable and showing the date
843 of birth of the person;

844 (4) The seller shall deliver the product directly into the custody of the
845 purchaser.

846 12. Pharmacists, intern pharmacists, and registered pharmacy technicians
847 shall implement and maintain an electronic log of each transaction. Such log shall
848 include the following information:

849 (1) The name, address, and signature of the purchaser;

850 (2) The amount of the compound, mixture, or preparation purchased;

851 (3) The date and time of each purchase; and

852 (4) The name or initials of the pharmacist, intern pharmacist, or registered
853 pharmacy technician who dispensed the compound, mixture, or preparation to the
854 purchaser.

855 13. Each pharmacy shall submit information regarding sales of any
856 compound, mixture, or preparation as specified in subdivision (3) of subsection 10
857 of this section in accordance with transmission methods and frequency established
858 by the department by regulation;

859 14. No person shall dispense, sell, purchase, receive, or otherwise acquire
860 quantities greater than those specified in this chapter.

861 15. All persons who dispense or offer for sale pseudoephedrine and
862 ephedrine products in a pharmacy shall ensure that all such products are located
863 only behind a pharmacy counter where the public is not permitted.

864 16. The penalties for a knowing or reckless violation of the provisions of
865 subsections 11 to 15 of this section are found in section 579.060.

866 17. The scheduling of substances specified in subdivision (3) of subsection
867 10 of this section and subsections 11, 12, 14, and 15 of this section shall not apply

868 to any compounds, mixtures, or preparations that are in liquid or liquid-filled gel
869 capsule form or to any compound, mixture, or preparation specified in subdivision
870 (3) of subsection 10 of this section which must be dispensed, sold, or distributed in
871 a pharmacy pursuant to a prescription.

872 18. The manufacturer of a drug product or another interested party may
873 apply with the department of health and senior services for an exemption from this
874 section. The department of health and senior services may grant an exemption by
875 rule from this section if the department finds the drug product is not used in the
876 illegal manufacture of methamphetamine or other controlled or dangerous
877 substances. The department of health and senior services shall rely on reports
878 from law enforcement and law enforcement evidentiary laboratories in determining
879 if the proposed product can be used to manufacture illicit controlled substances.

880 19. The department of health and senior services shall revise and republish
881 the schedules annually.

882 20. The department of health and senior services shall promulgate rules
883 under chapter 536 regarding the security and storage of Schedule V controlled
884 substances, as described in subdivision (3) of subsection 10 of this section, for
885 distributors as registered by the department of health and senior services.

886 21. Logs of transactions required to be kept and maintained by this section
887 and section 195.417 shall create a rebuttable presumption that the person whose
888 name appears in the logs is the person whose transactions are recorded in the logs.

✓

Copy